ViroPharma

Shire links with US hospital for rare disease research

For example, the company has been steadily building its rare disease franchise over the last couple of years, with deals such as the 2013 purchase of Viropharma for £2bn, which brought

Shire boosts orphan drug pipeline with Meritage Pharma deal

Shire has obtained the rights to privately held Meritage Pharma, in connection with its acquisition of ViroPharma in late 2013. ... The acquisition was made possible in conjunction with the firm's $4.2bn takeover of ViroPharma in November 2013, further

Pharma deals during January 2015

Top of the table was the all cash acquisition of NPS Pharmaceuticals by Shire for a total of $5.2bn just one year on from its acquisition of ViroPharma.

Idera Pharmaceuticals names new CEO

Milano left rare disease specialist ViroPharma in January 2014 shortly after the company was acquired by Shire Pharmaceuticals. ... Milano spent nearly 20 years at ViroPharma serving as chief financial officer from 1997 to 2006 when he was named CEO.

Celgene wins orphan drug award at PMEA

Also recognised in the Rare Diseases and Orphan Drugs category at the London awards ceremony was Viropharma, which - alongside Havas Life Medicom - was highly commended for its campaign for Cinryze, a

[ Previous 5 results ] 1 2 3 4 5 6 7 [ Next 5 results ]